» Articles » PMID: 30885944

S100A4 Alters Metabolism and Promotes Invasion of Lung Cancer Cells by Up-regulating Mitochondrial Complex I Protein NDUFS2

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 2019 Mar 20
PMID 30885944
Citations 39
Authors
Affiliations
Soon will be listed here.
Abstract

It is generally accepted that alterations in metabolism are critical for the metastatic process; however, the mechanisms by which these metabolic changes are controlled by the major drivers of the metastatic process remain elusive. Here, we found that S100 calcium-binding protein A4 (S100A4), a major metastasis-promoting protein, confers metabolic plasticity to drive tumor invasion and metastasis of non-small cell lung cancer cells. Investigating how S100A4 regulates metabolism, we found that S100A4 depletion decreases oxygen consumption rates, mitochondrial activity, and ATP production and also shifts cell metabolism to higher glycolytic activity. We further identified that the 49-kDa mitochondrial complex I subunit NADH dehydrogenase (ubiquinone) Fe-S protein 2 (NDUFS2) is regulated in an S100A4-dependent manner and that S100A4 and NDUFS2 exhibit co-occurrence at significant levels in various cancer types as determined by database-driven analysis of genomes in clinical samples using cBioPortal for Cancer Genomics. Importantly, we noted that S100A4 or NDUFS2 silencing inhibits mitochondrial complex I activity, reduces cellular ATP level, decreases invasive capacity in three-dimensional growth, and dramatically decreases metastasis rates as well as tumor growth Finally, we provide evidence that cells depleted in S100A4 or NDUFS2 shift their metabolism toward glycolysis by up-regulating hexokinase expression and that suppressing S100A4 signaling sensitizes lung cancer cells to glycolysis inhibition. Our findings uncover a novel S100A4 function and highlight its importance in controlling NDUFS2 expression to regulate the plasticity of mitochondrial metabolism and thereby promote the invasive and metastatic capacity in lung cancer.

Citing Articles

Identification of DAP3 as candidate prognosis marker and potential therapeutic target for hepatocellular carcinoma.

Yuan L, Yue Z, Ma Q, Zhang P, Xiao F, Chen L Front Immunol. 2025; 16:1528853.

PMID: 40051634 PMC: 11882876. DOI: 10.3389/fimmu.2025.1528853.


Mitochondrial Dysfunction and Its Potential Molecular Interplay in Hypermobile Ehlers-Danlos Syndrome: A Scoping Review Bridging Cellular Energetics and Genetic Pathways.

Shirvani P, Shirvani A, Holick M Curr Issues Mol Biol. 2025; 47(2).

PMID: 39996855 PMC: 11854588. DOI: 10.3390/cimb47020134.


Exploring Aerobic Energy Metabolism in Breast Cancer: A Mutational Profile of Glycolysis and Oxidative Phosphorylation.

Oliveira R, Cavalcante G, Soares-Souza G Int J Mol Sci. 2024; 25(23).

PMID: 39684297 PMC: 11641591. DOI: 10.3390/ijms252312585.


Smad4 Deficiency in S100A4 Macrophages Enhances Colitis-associated Tumorigenesis by Promoting Macrophage Lipid Metabolism Augmented M2 Polarization.

Liu T, Zhang X, Yan X, Cheng L, Yan X, Zeng F Int J Biol Sci. 2024; 20(15):6114-6129.

PMID: 39664586 PMC: 11628331. DOI: 10.7150/ijbs.98529.


Enhanced Oxidative Phosphorylation Driven by TACO1 Mitochondrial Translocation Promotes Stemness and Cisplatin Resistance in Bladder Cancer.

Deng M, Zhou Z, Chen J, Li X, Liu Z, Ye J Adv Sci (Weinh). 2024; 12(5):e2408599.

PMID: 39656941 PMC: 11791945. DOI: 10.1002/advs.202408599.


References
1.
Bresnick A, Weber D, Zimmer D . S100 proteins in cancer. Nat Rev Cancer. 2015; 15(2):96-109. PMC: 4369764. DOI: 10.1038/nrc3893. View

2.
Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

3.
Lunt S, Vander Heiden M . Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annu Rev Cell Dev Biol. 2011; 27:441-64. DOI: 10.1146/annurev-cellbio-092910-154237. View

4.
Pan J, Ding K, Wang C . Niclosamide, an old antihelminthic agent, demonstrates antitumor activity by blocking multiple signaling pathways of cancer stem cells. Chin J Cancer. 2012; 31(4):178-84. PMC: 3777479. DOI: 10.5732/cjc.011.10290. View

5.
Stewart R, Carpenter B, West D, Knifley T, Liu L, Wang C . S100A4 drives non-small cell lung cancer invasion, associates with poor prognosis, and is effectively targeted by the FDA-approved anti-helminthic agent niclosamide. Oncotarget. 2016; 7(23):34630-42. PMC: 5085181. DOI: 10.18632/oncotarget.8969. View